因内幕交易，800亿药企高管被罚500万，涉事重组交易终止

Core Viewpoint - The article discusses the administrative penalty imposed on Pan Weidong, an executive director of CSPC Pharmaceutical Group, for insider trading, resulting in a fine of 5 million RMB by the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Insider Trading Incident - The incident began in December 2023 when CSPC's subsidiary, CSPC Enbipu Pharmaceutical Co., planned to increase its stake in CSPC Innovation Pharmaceutical Co. (stock name "Xinnuo Wei") up to 100 million RMB [2]. - Pan Weidong, who was aware of insider information regarding a restructuring transaction, bought 2.74258 million shares of CSPC Innovation between December 8 and December 20, 2023, totaling approximately 99.99 million RMB [2]. - The CSRC determined that Pan's actions constituted insider trading, leading to the penalty and the requirement to handle illegally held securities [2]. Group 2: Company Operations and Financial Performance - CSPC Group's business operations remain normal despite the penalty, and the company does not expect any negative impact on its overall business [3]. - CSPC Group reported a revenue of 29.009 billion RMB in 2024, a decline of 9.56% year-on-year, with a net profit of 4.328 billion RMB, down 25.90%, marking the first decline in ten years for both revenue and profit [4]. - In the first half of 2024, CSPC continued to experience a downward trend, with revenue of 13.273 billion RMB, a decrease of 20.04%, and a net profit of 2.548 billion RMB, down 15.64% [4]. Group 3: CSPC Innovation's Performance - CSPC Innovation, formerly known as CSPC Xinnuo Wei Pharmaceutical Co., has also faced declining revenues in 2023 and 2024, but showed a recovery with a 7.71% year-on-year increase in revenue to 1.593 billion RMB in the first three quarters of the current year [6]. - The net profit for CSPC Innovation saw a significant drop of 87.63% in 2024, followed by a loss of 0.24 billion RMB in the first three quarters of the current year, marking its first loss [6].